Loading
A phase 1/2 trial of HY05350 for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07083323 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 262 participants planned, started 2025-07-22 and due to reach its primary completion in 2028-03-31. Interventions recorded: HY05350 for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/